An Open Letter to Familial Chylomicronemia Syndrome Patients Regarding Access to Therapy

As clinicians with the privilege of taking care of patients with Familial Chylomicronemia Syndrome (FCS), we support your efforts to urge the United States Food and Drug Administration (FDA) to approve volanesorsen, particularly in light of there currently being no other effective medical therapy for FCS.